LAVACCHI, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.068
EU - Europa 2.545
AS - Asia 2.413
SA - Sud America 199
AF - Africa 59
OC - Oceania 27
Totale 8.311
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.984
RU - Federazione Russa 880
IT - Italia 863
CN - Cina 681
SG - Singapore 675
HK - Hong Kong 287
VN - Vietnam 197
KR - Corea 187
IE - Irlanda 159
BR - Brasile 155
BD - Bangladesh 141
PL - Polonia 114
SE - Svezia 105
FR - Francia 92
DE - Germania 86
FI - Finlandia 78
IN - India 61
CA - Canada 50
JP - Giappone 44
NL - Olanda 42
ID - Indonesia 39
GB - Regno Unito 37
JO - Giordania 36
AU - Australia 27
AT - Austria 19
MX - Messico 18
CH - Svizzera 16
ES - Italia 15
IQ - Iraq 14
NG - Nigeria 13
ZA - Sudafrica 11
AR - Argentina 10
PK - Pakistan 10
UA - Ucraina 9
CI - Costa d'Avorio 8
AE - Emirati Arabi Uniti 7
CL - Cile 7
EC - Ecuador 7
BJ - Benin 6
GR - Grecia 6
PE - Perù 6
PH - Filippine 6
VE - Venezuela 6
MA - Marocco 5
AL - Albania 4
CO - Colombia 4
EG - Egitto 4
TR - Turchia 4
BE - Belgio 3
CZ - Repubblica Ceca 3
DZ - Algeria 3
HN - Honduras 3
KE - Kenya 3
LT - Lituania 3
OM - Oman 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
BB - Barbados 2
CR - Costa Rica 2
GT - Guatemala 2
KZ - Kazakistan 2
LV - Lettonia 2
NO - Norvegia 2
NP - Nepal 2
PY - Paraguay 2
RO - Romania 2
SA - Arabia Saudita 2
TW - Taiwan 2
UY - Uruguay 2
AZ - Azerbaigian 1
BH - Bahrain 1
BS - Bahamas 1
ET - Etiopia 1
GA - Gabon 1
GH - Ghana 1
HR - Croazia 1
IL - Israele 1
IR - Iran 1
JM - Giamaica 1
KW - Kuwait 1
MD - Moldavia 1
MK - Macedonia 1
MM - Myanmar 1
MY - Malesia 1
NI - Nicaragua 1
PA - Panama 1
PS - Palestinian Territory 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TG - Togo 1
TH - Thailandia 1
TJ - Tagikistan 1
TN - Tunisia 1
Totale 8.311
Salva come PNG Salva come JPEG
Città #
Santa Clara 747
Ashburn 510
Singapore 498
Hong Kong 259
Hefei 202
Seoul 186
San Jose 174
Dublin 157
Milan 131
Florence 117
Warsaw 110
Fairfield 92
Council Bluffs 85
Beijing 80
Chandler 75
Los Angeles 73
Moscow 62
Buffalo 60
The Dalles 56
Ho Chi Minh City 55
Dallas 51
Woodbridge 48
Munich 47
Rome 44
Lauterbourg 43
Hanoi 42
Tokyo 39
New York 38
Altamura 36
Seattle 36
Helsinki 35
Jakarta 35
Lawrence 35
Cambridge 34
Houston 33
Boardman 32
Shanghai 32
Paris 29
Melbourne 26
Wilmington 26
Brescia 25
Ann Arbor 24
Lappeenranta 24
Kent 22
Naples 22
Princeton 20
Toronto 19
Mumbai 18
Boston 17
Chicago 17
Guangzhou 17
Vienna 17
Bologna 16
Turin 16
Turku 16
London 15
Bengaluru 13
Haiphong 13
São Paulo 13
Abuja 12
Bern 12
Frankfurt am Main 12
Orem 10
Mexico City 9
Palermo 9
Tianjin 9
Abidjan 8
Dhaka 8
Genoa 8
Johannesburg 8
Montreal 8
Phoenix 8
Pune 8
Redondo Beach 8
San Francisco 8
Amsterdam 7
Bremen 7
San Diego 7
Atlanta 6
Charlotte 6
Chennai 6
Cotonou 6
Curitiba 6
Dong Ket 6
Medford 6
Miano 6
Padua 6
Rio de Janeiro 6
Stockholm 6
Vũng Tàu 6
West Jordan 6
Ancona 5
Arezzo 5
Falls Church 5
Figino 5
Hillsboro 5
Lucca 5
Nuremberg 5
Ottawa 5
Salt Lake City 5
Totale 5.103
Salva come PNG Salva come JPEG
Nome #
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. 286
Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions 262
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer 247
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 234
Aflibercept plus folfiri as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience 224
Metastatic intracranial solitary fibrous tumors/hemangiopericytomas: description of two cases with radically different behaviors and review of the literature 220
A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy 215
KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation 210
Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality? 206
Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy 204
Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report 203
Association of systemic steroid treatment and outcome in patients treated with immune checkpoint inhibitors: A real-world analysis 201
Stable disease in a patient with metastatic leiomyosarcoma treated with trabectedin 197
Added prognostic value of molecular imaging parameters over proliferation index in typical lung carcinoid: an [18F]FDG PET/CT and SSTR imaging study 182
KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population 181
Results of the observational prospective RealFLOT study 180
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 178
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 177
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 176
Pathological complete response achieved with FLOT chemotherapy in two patients with MSI-H esophagogastric junction and gastric adenocarcinoma 171
Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI 165
Vinorelbine in non-small cell lung cancer: Real-World data from a single institution experience 164
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination 163
Long-term response of more than 9 years to regorafenib in a heavily pretreated patient with metastatic colorectal cancer 162
KRAS-related miR-143 expression is associated with lymph node involvement and correlates with outcome in pancreatic adenocarcinoma patients 162
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 160
Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience 157
Liquid biopsy in colorectal cancer: No longer young, but not yet old 154
Immune checkpoint inhibitors in the treatment of renal cancer: Current state and future perspective 154
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 149
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer 146
Prognostic role of hERG1 Potassium Channels in Neuroendocrine Tumours of the Ileum and Pancreas 144
Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer 136
Tumor-Agnostic Treatment for Cancer: When How is Better than Where 133
Early changes in circulating tumor DNA (ctDNA) predict treatment response in metastatic KRAS-mutated colorectal cancer (mCRC) patients 133
Primary pleural epithelioid hemangioendothelioma: case report and review of the literature 130
Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer. 129
REBECA trial: A new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer 129
Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge 126
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 119
Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study 118
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 104
MSI and EBV Positive Gastric Cancer's Subgroups and Their Link With Novel Immunotherapy 101
Treatment Strategy for Oligometastatic Gastric Cancer: Brief Considerations 93
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 92
Electronic nicotine delivery systems (ENDS): not still ready to put on END 88
The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm? 81
A Snapshot from the Italian Clinical Practice Regarding Efficacy and Utility Rate of Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: The RealBLADDER Study 55
Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study 49
Beneath the surface of colorectal cancer: Unmasking the evolving nature of (Neo)RAS 44
Radiomics-based prediction of microsatellite instability in colorectal cancer: a non-invasive approach to treatment stratification 43
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 42
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 42
Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: Results from the MAVERIC Phase II Trial (1499 WORDS MAIN TEXT) 41
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 41
Immune checkpoint inhibitors in the first-line treatment of esophageal squamous cell carcinoma: Minireview for a big shift 40
Prediction of Microsatellite Instability in Colorectal Cancer Using Two Internally Validated Radiomic Models 35
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study 35
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 33
Transcriptomic analysis on pancreatic adenocarcinoma patients uncovers KRAS-mediated PPAR pathway alteration 30
Radiomics on 177Lu-DOTATATE Posttreatment Scans: Feasibility, Preprocessing Optimization, and Planar-SPECT Comparison 26
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study 26
Microbiome dysbiosis and KRAS-driven tumorigenesis in pancreatic cancer: implications for immune checkpoint inhibitors efficacy 20
Navigating Disappearing Liver Metastases in Colorectal Cancer: A Review of Surgical and Non-Surgical Approaches 19
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers 17
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 16
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 11
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 9
Totale 8.420
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.909
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.909
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022161 7 4 14 4 3 7 4 28 8 14 24 44
2022/2023571 33 108 30 36 20 101 78 48 61 14 20 22
2023/2024579 15 21 45 53 50 53 28 121 20 67 48 58
2024/20252.671 79 214 146 430 628 359 71 156 141 101 160 186
2025/20263.969 402 452 415 266 368 130 417 229 281 301 263 445
2026/202711 11 0 0 0 0 0 0 0 0 0 0 0
Totale 8.420